person · Reporting owner
ROSENWALD LINDSAY A MD
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | September 23, 2024 | September 25, 2024 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director · PRESIDENT, CEO & CHAIRMAN · 10% owner | March 18, 2026 | March 20, 2026 |
| Journey Medical CorpDERM · Entity 6273 | Director | June 25, 2026 | June 26, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | July 05, 2023 | July 07, 2023 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | 10% owner | September 12, 2016 | September 22, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2034-09-23 | Direct | 30,000 |
Reported balance
After 2024-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.
Fortress Biotech, Inc.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001SEC Table I · non-derivative | Direct | 4,586,841 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 475,424 · Balance 4,586,841 F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.
Journey Medical Corp
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 221,146 |
Reported balance
After 2026-06-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 10,000 · Balance 221,146 F1: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027. F2: Includes restricted stock units, which vest over various time periods. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 176,470 |
Reported balance
Holding disclosure · report date 2026-06-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 176,470 F3: The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027.
F2: Includes restricted stock units, which vest over various time periods.
F3: The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power.
MUSTANG BIO, INC.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 60,525 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 7,246 · Balance 60,525 F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Includes restricted share units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date.
F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Includes restricted share units, which vest over various time periods.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 22, 2016
Jointly reported with FBIO Acquisition, Inc., Fortress Biotech, Inc., Opus Point Partners, LLC, Opus Point Healthcare Innovations (Offshore) Fund Ltd., WEISS MICHAEL S
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,037,482 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,037,482 F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 371,584 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 371,584 F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,530 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 89,530 F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,884 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,884 F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,294 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,294 F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 157,007 |
Reported balance
After 2025-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 12,195 · Balance 157,007 F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 207,007 |
Reported balance
After 2025-05-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 50,000 · Balance 207,007 |
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 207,007 · Balance 0 F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board.
F2: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jul 8, 2021 20:32 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 13,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-090243 · tm2121675-4_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,253 F1 · shares: The Reporting Person was granted 13,774 restricted shares pursuant to the Issuer's 2016 Incentive Plan on June 28, 2021. The shares will vest on June 17, 2024, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 16,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-080362 · tm2119513-3_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,782 F1 · shares: The 16,502 shares of restricted Common Stock will vest on June 10, 2024, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| June 01, 2021 Filed Apr 29, 2022 20:22 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,297 | $2.31 | $2,996.07 |
DisclosureSEC source: 0001104659-22-053615 · tm2213913-6_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,408,336 F1 · kind: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| February 26, 2021 Filed Mar 15, 2021 10:31 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 1,043 | $2.83 | $2,951.69 |
DisclosureSEC source: 0001104659-21-035854 · tm219639d2_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,479 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2020 and ending on February 28, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on September 1, 2020 (the purchase date of the offering period). F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 21:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,030,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048830 · tm219139d6_4.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,407,039 F2 · shares: The Reporting Person was granted 1,030,339 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2021. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 13:15 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 100,000 | $2.66 | $266,000.00 |
DisclosureSEC source: 0001104659-20-135513 · tm2038479d1_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,423 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the purchase transactions on December 14, 2020, was $2.59 to $2.73. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| December 14, 2020 Filed Dec 22, 2020 21:21 UTC Amendment | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 100,000 | $2.66 | $266,000.00 |
DisclosureSEC source: 0001104659-20-138584 · tm2039180-3_4a.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,436 F3 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on December 14, 2020, was $2.59 to $2.73. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted share units, which vest over various time periods. F4 · balance_after: 1,183 ESPP shares were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on December 15, 2020. Read SEC document |
| December 01, 2020 Filed Apr 9, 2021 21:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,250 | $2.34 | $2,925.00 |
DisclosureSEC source: 0001104659-21-048830 · tm219139d6_4.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,376,700 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| August 31, 2020 Filed Dec 22, 2020 21:21 UTC Amendment | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 1,182 | $2.48 | $2,931.36 |
DisclosureSEC source: 0001104659-20-138584 · tm2039180-3_4a.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,436 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2020 and ending on August 31, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the purchase date of the offering period). F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| August 26, 2020 Filed Sep 1, 2020 12:32 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 52,500 | $18.00 | $945,000.00 |
DisclosureSEC source: 0001104659-20-101100 · tm2029961-1_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 20:32 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096925 · tm2028955d3_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,423 F1 · balance_after: Includes 100,423 restricted stock units which vest over time. Read SEC document |
| July 14, 2020 Filed Dec 22, 2020 21:20 UTC Amendment | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 16,611 | $2.48 | $41,195.28 |
DisclosureSEC source: 0001104659-20-138582 · tm2039180-2_4a.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,254 F2 · balance_after: Includes restricted share units, which vest over various time periods. F3 · balance_after: 831 ESPP shares were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on August 19, 2020. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:33 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 24,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-071416 · tm2022118d6_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,280 F1 · shares: The 24,390 shares of restricted Common Stock will vest on June 5, 2023, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| June 01, 2020 Filed Apr 9, 2021 21:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,602 | $1.69 | $2,707.38 |
DisclosureSEC source: 0001104659-21-048830 · tm219139d6_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375,450 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| February 28, 2020 Filed Dec 22, 2020 21:20 UTC Amendment | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 831 | $2.48 | $2,060.88 |
DisclosureSEC source: 0001104659-20-138582 · tm2039180-2_4a.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,643 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2019 and ending on February 29, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the last trading day of the offering period) F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 801,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033116 · tm2011481-6_form4.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,373,848 F2 · shares: The Reporting Person was granted 801,536 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2020. Read SEC document |
| December 01, 2019 Filed Mar 13, 2020 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 1,123 | $2.06 | $2,313.38 |
DisclosureSEC source: 0001104659-20-033116 · tm2011481-6_form4.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572,312 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 13:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | PurchaseCOMMON STOCK | 100,000 | $1.27 | $127,000.00 |
DisclosureSEC source: 0001104659-19-066411 · tm19236741_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,890 F1 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 22:42 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005208 · tm203350d1_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,812 F1 · balance_after: Includes 33,812 restricted stock units which vest over time. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 11:00 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 396,825 | $1.26 | $499,999.50 |
DisclosureSEC source: 0001144204-19-035107 · tv525484_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,569,722 F1 · kind: Shares acquired as a result of prepayment of debt owed to Dr. Rosenwald that was held in the name of Opus Point Healthcare Innovations Fund, LP ("Opus"), an investment fund co-owned by Dr. Rosenwald, in the form of the Company's common stock (measured at the closing price on July 18, 2019), under that certain Amended & Restated Credit Facility Agreement, dated as of March 12, 2018, by and between the Company and Opus. F1 · shares: Shares acquired as a result of prepayment of debt owed to Dr. Rosenwald that was held in the name of Opus Point Healthcare Innovations Fund, LP ("Opus"), an investment fund co-owned by Dr. Rosenwald, in the form of the Company's common stock (measured at the closing price on July 18, 2019), under that certain Amended & Restated Credit Facility Agreement, dated as of March 12, 2018, by and between the Company and Opus. F1 · price: Shares acquired as a result of prepayment of debt owed to Dr. Rosenwald that was held in the name of Opus Point Healthcare Innovations Fund, LP ("Opus"), an investment fund co-owned by Dr. Rosenwald, in the form of the Company's common stock (measured at the closing price on July 18, 2019), under that certain Amended & Restated Credit Facility Agreement, dated as of March 12, 2018, by and between the Company and Opus. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:48 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 11,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031021 · tv523632_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,890 F1 · shares: The 11,442 shares of restricted Common Stock will vest on June 13, 2022, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Dr. Rosenwald's continued service on the board. Read SEC document |
| June 03, 2019 Filed Mar 13, 2020 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 1,467 | $1.10 | $1,613.70 |
DisclosureSEC source: 0001104659-20-033116 · tm2011481-6_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO & CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,571,189 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 20:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 648,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019499 · tv516220_4.xml · nonDerivative · entry 4 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,172,897 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. Read SEC document |
| December 01, 2018 Filed Apr 12, 2019 20:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 1,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019499 · tv516220_4.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,524,693 F3 · shares: Shares were acquired pursuant to the Company's Employee Stock Purchase Plan. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 17:23 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | PurchaseCOMMON STOCK | 49,666 | $2.35 | $116,715.10 |
DisclosureSEC source: 0001144204-18-059191 · tv507113_4.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,448 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on November 7, 2018, was $2.05 to $2.26, the range of prices for the sale transactions on November 8, 2018, was $2.19 to $2.34, and the range of prices for the sale transactions on November 9, 2018, was $2.30 to $2.44. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units which vest over various time periods, subject to Dr. Rosenwald's continued service on the board on such date. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 17:23 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | PurchaseCOMMON STOCK | 48,234 | $2.24 | $108,044.16 |
DisclosureSEC source: 0001144204-18-059191 · tv507113_4.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,782 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on November 7, 2018, was $2.05 to $2.26, the range of prices for the sale transactions on November 8, 2018, was $2.19 to $2.34, and the range of prices for the sale transactions on November 9, 2018, was $2.30 to $2.44. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units which vest over various time periods, subject to Dr. Rosenwald's continued service on the board on such date. Read SEC document |
| November 07, 2018 Filed Nov 13, 2018 17:23 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | PurchaseCOMMON STOCK | 2,100 | $2.12 | $4,452.00 |
DisclosureSEC source: 0001144204-18-059191 · tv507113_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,548 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on November 7, 2018, was $2.05 to $2.26, the range of prices for the sale transactions on November 8, 2018, was $2.19 to $2.34, and the range of prices for the sale transactions on November 9, 2018, was $2.30 to $2.44. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units which vest over various time periods, subject to Dr. Rosenwald's continued service on the board on such date. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 01:06 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 50,000 | $4.41 | $220,500.00 |
DisclosureSEC source: 0001144204-18-057391 · tv506421_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 01:46 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 14,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042960 · tv500469_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,663 F1 · shares: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2 · balance_after: Includes 24,663 shares of restricted stock. Read SEC document |
| July 03, 2018 Filed Apr 12, 2019 20:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 164,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019499 · tv516220_4.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,523,179 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 21:23 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 16,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-034455 · tv496607_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,448 F1 · shares: The 16,448 shares of restricted Common Stock will vest on June 14, 2021, subject to Dr. Rosenwald's continued service on the board on such date. F2 · balance_after: Represents shares of restricted Common Stock which vest over various time periods. Read SEC document |
| June 14, 2018 Filed Jan 17, 2020 22:41 UTC Amendment | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005207 · tm203350d6_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: 10,000 restricted stock units were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on 11/05/2018. F2 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 21:37 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 5,234 | $4.34 | $22,715.56 |
DisclosureSEC source: 0001144204-18-033791 · tv496320_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,234 F1 · price: Weighted average price. These shares were purchased in multiple transactions ranging from $4.20 to $4.40. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth. F2 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 5,234 | $4.34 | $22,726.55 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 6 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 07, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 14,800 | $4.32 | $63,968.56 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 5 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,766 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 06, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 9,100 | $4.35 | $39,575.90 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 4 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,966 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 05, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 8,400 | $4.28 | $35,948.64 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,866 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 04, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 3,800 | $4.19 | $15,920.86 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,466 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| June 01, 2018 Filed Jun 12, 2018 21:31 UTC Amendment | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 8,666 | $4.15 | $36,002.90 |
DisclosureSEC source: 0001144204-18-033938 · tv496382_form4a.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,666 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| January 01, 2018 Filed Apr 12, 2019 20:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 586,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019499 · tv516220_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358,706 F1 · shares: The Reporting Person was granted 586,428, 164,473 and 648,204 restricted shares pursuant to the Company's Long Term Incentive Plan on January 1, 2018, July 3, 2018 and January 1, 2019, respectively. F2 · balance_after: Includes 1,346 shares acquired pursuant to the Company's Employee Stock Purchase Plan. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 23:02 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseSERIES A CUMULATIVE REDEEMABLE PERPETUAL PREFERRED STOCK | 40,000 | $25.00 | $1,000,000.00 |
DisclosureSEC source: 0001144204-17-057351 · tv478998_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · PRESIDENT, CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 12:36 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 1,350 | $5.40 | $7,290.00 |
DisclosureSEC source: 0001144204-17-051784 · tv476670_form4.xml · nonDerivative · entry 4 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 12:36 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 2,900 | $5.63 | $16,327.00 |
DisclosureSEC source: 0001144204-17-051784 · tv476670_form4.xml · nonDerivative · entry 3 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,650 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| October 05, 2017 Filed Oct 10, 2017 12:36 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 3,550 | $5.60 | $19,880.00 |
DisclosureSEC source: 0001144204-17-051784 · tv476670_form4.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| October 04, 2017 Filed Oct 10, 2017 12:36 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 2,200 | $5.60 | $12,320.00 |
DisclosureSEC source: 0001144204-17-051784 · tv476670_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,200 F1 · balance_after: Includes 10,000 shares of restricted stock. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-036573 · v470709_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The 10,000 shares of restricted Common Stock will vest on July 10, 2020, subject to Dr. Rosenwald's continued service on the board on such date. F1 · balance_after: The 10,000 shares of restricted Common Stock will vest on July 10, 2020, subject to Dr. Rosenwald's continued service on the board on such date. Read SEC document |
| January 01, 2017 Filed Jan 27, 2017 21:12 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 552,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000116 · doc4_4441.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,857,168 F2 · shares: Represents an award of restricted shares of the Issuer's common stock made pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan. Read SEC document |
| December 01, 2016 Filed Jan 27, 2017 21:12 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCommon Stock, par value $0.001 | 731 | $2.03 | $1,483.93 |
DisclosureSEC source: 0001638599-17-000116 · doc4_4441.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304,470 F1 · shares: These shares were acquired under the Issuer's 2012 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.